Expert panel backs continued use of 3 asthma drugs

An expert panel assembled by the FDA has recommended that three asthma drugs -- Advair, Serevent, and Foradil -- remain on the market with an adjustment in warning labels. The panel concluded that despite evidence that the drugs are linked to a small increase in the number of patient deaths, the benefits exceed the risks. The FDA will consider the recommendation and make a final ruling.

- read this report from KIDK TV for more

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.